<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213757</url>
  </required_header>
  <id_info>
    <org_study_id>2014-071</org_study_id>
    <nct_id>NCT02213757</nct_id>
  </id_info>
  <brief_title>Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)</brief_title>
  <acronym>EVER</acronym>
  <official_title>Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH): A Randomized Controlled Trial [EVER Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vaginal estrogen use is associated with&#xD;
      resolution of blood in the urine (microscopic hematuria) in postmenopausal women. The&#xD;
      hypothesis is that postmenopausal women with blood in the urine (microscopic hematuria) will&#xD;
      have higher rates of resolution of hematuria after treatment course with vaginal conjugated&#xD;
      equine estrogen cream compared to placebo cream&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial of vaginal estrogen cream for postmenopausal women with&#xD;
      microscopic hematuria (AMH). Potential subjects will be screened with a dipstick urinalysis&#xD;
      of a catheterized urine specimen, followed by microscopic urinalysis and urine culture if&#xD;
      urine dipstick is positive for trace blood or greater. Women who are identified as having&#xD;
      asymptomatic microscopic hematuria (&gt;3 red blood cells (RBC) per high powered field (hpf)) on&#xD;
      a single urine microscopy specimen in the absence of urinary tract infection or other benign&#xD;
      cause will be eligible for enrollment.&#xD;
&#xD;
      Women meeting inclusion criteria will be randomized to either conjugated equine estrogen&#xD;
      cream (Premarin, 0.625mg conjugated estrogens) or placebo cream for 8 weeks. Microscopic&#xD;
      urinalysis of a catheterized urine specimen will be re-checked at 8 weeks to check for&#xD;
      reduction, resolution or persistence of AMH. During the 8 weeks of vaginal estrogen or&#xD;
      placebo, women will complete the recommended AMH workup as dictated by the American Urologic&#xD;
      Association (AUA) guidelines (cystourethroscopy, serum blood urea nitrogen and creatinine&#xD;
      levels, and computed tomography (CT) scan of the abdomen and pelvis with and without&#xD;
      intravenous contrast).1&#xD;
&#xD;
      Validated questionnaires to assess vaginal atrophy and symptoms of urinary urgency and&#xD;
      frequency will be completed at time of randomization and again at 8 weeks. Cost analysis of&#xD;
      the standard AMH workup (cystourethroscopy and CT scan) versus empiric treatment with 8 weeks&#xD;
      of vaginal estrogen cream will be calculated based on Medicare reimbursement, as well as&#xD;
      market price for vaginal estrogen cream Additionally, patients will be asked to complete a&#xD;
      questionnaire to assess the level of bother associated with completing the current AMH workup&#xD;
      of CT scan and cystoscopy as compared to completing a treatment course of vaginal estrogen&#xD;
      cream.&#xD;
&#xD;
      Secondary analyses will determine whether there are additional benefits to a trial period of&#xD;
      vaginal estrogen cream in postmenopausal women with AMH prior to reflexively screening for&#xD;
      urinary tract abnormalities. We will compare the cost of a standard AMH workup to a treatment&#xD;
      course of vaginal estrogen cream, to determine whether vaginal estrogen with potential&#xD;
      resolution of AMH is associated with any savings prior to pursuing further workup.&#xD;
      Additionally, questionnaires will ask study participants whether they would prefer to undergo&#xD;
      the current AUA AMH workup or a treatment course of vaginal cream, in order to assess bother&#xD;
      and anxiety associated with these interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of microscopic hematuria</measure>
    <time_frame>8 weeks</time_frame>
    <description>Microscopic urinalysis will be performed after an 8 week trial of vaginal estrogen or placebo. Resolution of microscopic hematuria is defined according to AUA guidelines, &lt;3 red blood cells per high powered field.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary urgency and frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine the effect of vaginal estrogen compared to placebo on symptoms of urinary frequency and urgency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Microscopic Hematuria</condition>
  <arm_group>
    <arm_group_label>Premarin vaginal cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaginal cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin vaginal estrogen cream</intervention_name>
    <arm_group_label>Premarin vaginal cream</arm_group_label>
    <other_name>Conjugated estrogens vaginal cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vaginal cream</intervention_name>
    <description>Inactive vaginal cream manufactured to mimic Premarin vaginal cream</description>
    <arm_group_label>Placebo vaginal cream</arm_group_label>
    <other_name>Other names have not been specified</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal women&#xD;
&#xD;
          -  Asymptomatic microscopic hematuria (three or more red blood cells per high powered&#xD;
             field on a single urine microscopy) in the absence of urinary tract infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known urologic disease&#xD;
&#xD;
          -  Presence of gross hematuria&#xD;
&#xD;
          -  Presence of indwelling urologic foreign body (foley catheter, ureteral stent)&#xD;
&#xD;
          -  Inability to obtain intravenous contrast CT scan (elevated creatinine, severe contrast&#xD;
             allergy)&#xD;
&#xD;
          -  History of pelvic irradiation or malignancy&#xD;
&#xD;
          -  Not a candidate for vaginal estrogen&#xD;
&#xD;
               -  Allergy to vaginal estrogen&#xD;
&#xD;
               -  Current or prior diagnosis of breast or endometrial cancer&#xD;
&#xD;
               -  History of deep vein thrombosis/pulmonary embolus&#xD;
&#xD;
               -  Hypercoagulable state&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl B Iglesia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee A Richter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.auanet.org/guidelines/asymptomatic-microhematuria-(amh)-guideline</url>
    <description>American Urologic Association Asymptomatic Microscopic Hematuria Guidelines</description>
  </link>
  <results_reference>
    <citation>Wu JM, Williams KS, Hundley AF, Jannelli ML, Visco AG. Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms. Am J Obstet Gynecol. 2006 May;194(5):1423-6. Epub 2006 Mar 30.</citation>
    <PMID>16579943</PMID>
  </results_reference>
  <results_reference>
    <citation>Shalom DF, Lin SN, St Louis S, Lind LR, Winkler HA. The prevalence of microscopic hematuria in women with pelvic organ prolapse. Female Pelvic Med Reconstr Surg. 2011 Nov;17(6):290-2. doi: 10.1097/SPV.0b013e3182357afb.</citation>
    <PMID>22453223</PMID>
  </results_reference>
  <results_reference>
    <citation>Jung H, Gleason JM, Loo RK, Patel HS, Slezak JM, Jacobsen SJ. Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J Urol. 2011 May;185(5):1698-703. doi: 10.1016/j.juro.2010.12.093. Epub 2011 Mar 21.</citation>
    <PMID>21419446</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>August 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematuria</keyword>
  <keyword>Menopause</keyword>
  <keyword>Urinalysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

